Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
With a weight-of-the-evidence approach, cancer risk assessment indentifies hazards, determines dose-response relationships, and assesses exposure to characterize the true risk. This book focuses on the quantitative methods for conducting chemical cancer risk assessments for solvents, metals, mixtures, and nanoparticles. It links these to the basic toxicology and biology of cancer, along with the impacts on regulatory guidelines and standards. By providing insightful perspective, Cancer Risk Assessment helps researchers develop a discriminate eye when it comes to interpreting data accurately and separating relevant information from erroneous.…mehr
With a weight-of-the-evidence approach, cancer risk assessment indentifies hazards, determines dose-response relationships, and assesses exposure to characterize the true risk. This book focuses on the quantitative methods for conducting chemical cancer risk assessments for solvents, metals, mixtures, and nanoparticles. It links these to the basic toxicology and biology of cancer, along with the impacts on regulatory guidelines and standards. By providing insightful perspective, Cancer Risk Assessment helps researchers develop a discriminate eye when it comes to interpreting data accurately and separating relevant information from erroneous.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
CHING-HUNG HSU, PhD, DABT, is a Vice President at TaiGen Biotechnology Co., Ltd. His professional experience includes positions at Merck & Co., Inc., the U.S. Environmental Protection Agency, and the California Environmental Protection Agency. Dr. Hsu earned his BS from the National Taiwan University and PhD from the Massachusetts Institute of Technology. He completed his postdoctoral training at the University of California at Berkeley. Dr. Hsu is board-certified in toxicology by the American Board of Toxicology. He has published numerous professional papers, book chapters, and technical reports. Dr. Hsu serves on the Editorial Board of two international peer-reviewed journals. TODD STEDEFORD, PhD, JD, DABT, is a Toxicology Advisor and In-house Counsel for a multinational specialty chemical manufacturer. Previously, he was a human health toxicologist with the U.S. Environmental Protection Agency and an adjunct scientist with the Polish Academy of Sciences. Dr. Stedeford is board-certified in toxicology by the American Board of Toxicology and licensed to practice law in the District of Columbia and the State of Louisiana. He has authored over eighty publications including peer-reviewed scientific articles, government health assessments, legal articles, and scientific and legal book chapters.
Inhaltsangabe
PREFACE. CONTRIBUTORS. ABBREVIATIONS AND ACRONYMS. PART I CANCER RISK ASSESSMENT, SCIENCE POLICY, AND REGULATORY FRAMEWORKS. CHAPTER 1 CANCER RISK ASSESSMENT(Elizabeth L. Anderson, Kimberly Lowe, and Paul Turnham). References. CHAPTER 2 SCIENCE POLICY AND CANCER RISK ASSESSMENT (Gary E. Marchant). References. CHAPTER 3 HAZARD AND RISK ASSESSMENT OF CHEMICAL CARCINOGENICITY WITHIN A REGULATORY CONTEXT (Henk Tennekes, Virginia A. Gretton, and Todd Stedeford). References. CHAPTER 4 USE OF CANCER RISK ASSESSMENTS IN DETERMINATION OF REGULATORY STANDARDS (Robert A. Howd and Anna M. Fan). References. PART II CANCER BIOLOGY AND TOXICOLOGY. CHAPTER 5 THE INTERPLAY OF CANCER AND BIOLOGY (James W. Holder). References. CHAPTER 6 CHEMICAL CARCINOGENESIS: A BRIEF HISTORY OF ITS CONCEPTS WITH A FOCUS ON POLYCYCLIC AROMATIC HYDROCARBONS (Stephen Nesnow). References. CHAPTER 7 HORMESIS AND CANCER RISKS: ISSUES AND RESOLUTION (Paolo F. Ricci and Edward J. Calabrese). References. CHAPTER 8 THRESHOLDS FOR GENOTOXIC CARCINOGENS: EVIDENCE FROM MECHANISM-BASED CARCINOGENICITY STUDIES (Shoji Fukushima, Min Wei, Anna Kakehashi, and Hideki Wanibuchi). References. PART III GENETIC TOXICOLOGY, TESTING GUIDELINES AND REGULATIONS, AND NOVEL ASSAYS. CHAPTER 9 DEVELOPMENT OF GENETIC TOXICOLOGY TESTING AND ITS INCORPORATION INTO REGULATORY HEALTH EFFECTS TEST REQUIREMENTS (Errol Zeiger). References. CHAPTER 10 GENETIC TOXICOLOGY TESTING GUIDELINES AND REGULATIONS (Lutz Müller and Hans-Jörg Martus). References. CHAPTER 11 IN VITRO GENOTOX ASSAYS (David Kirkland and David Gatehouse). References. CHAPTER 12 IN VIVO GENOTOXICITY ASSAYS (Véronique Thybaud). References. PART IV ASSESSING THE HUMAN RELEVANCE OF CHEMICAL-INDUCED TUMORS. CHAPTER 13 FRAMEWORK ANALYSIS FOR DETERMINING MODE OF ACTION AND HUMAN RELEVANCE (R. Julian Preston). References. CHAPTER 14 EXPERIMENTAL ANIMAL STUDIES AND CARCINOGENICITY (Mary Elizabeth (Bette) Meek). References. CHAPTER 15 CANCER EPIDEMIOLOGY (Herman J. Gibb and Jessie P. Buckley). References. CHAPTER 16 RODENT HEPATOCARCINOGENESIS (James E. Klaunig). References. CHAPTER 17 MODE OF ACTION ANALYSIS AND HUMAN RELEVANCE OF LIVER TUMORS INDUCED BY PPARa ACTIVATION (J. Christopher Corton). References. CHAPTER 18 ALPHA2U-GLOBULIN NEPHROPATHY AND CHRONIC PROGRESSIVE NEPHROPATHY AS MODES OF ACTION FOR RENAL TUBULE TUMOR INDUCTION IN RATS, AND THEIR POSSIBLE INTERACTION (Edward A. Lock and Gordon C. Hard). References. CHAPTER 19 URINARY TRACT CALCULI AND BLADDER TUMORS (Samuel M. Cohen, Lora L. Arnold, and Shugo Suzuki). References. PART V METHODS FOR INFORMING CANCER RISK QUANTIFICATION. CHAPTER 20 (Q)SAR ANALYSIS OF GENOTOXIC AND NONGENOTOXIC CARCINOGENS: A STATE-OF-THE-ART OVERVIEW (Yin-tak Woo and David Y. Lai). References. CHAPTER 21 PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELS IN CANCER RISK ASSESSMENT (Mathieu Valcke and Kannan Krishnan). References. CHAPTER 22 GENOMICS AND ITS ROLE IN CANCER RISK ASSESSMENT (Banalata Sen, Douglas C. Wolf, and Vicki Dellarco). References. CHAPTER 23 COMPUTATIONAL TOXICOLOGY IN CANCER RISK ASSESSMENT (Jerry N. Blancato). References. PART VI GENERAL APPROACHES FOR QUANTIFYING CANCER RISKS. CHAPTER 24 LINEAR LOW-DOSE EXTRAPOLATIONS (Michael Dourson and Lynne Haber). References. CHAPTER 25 QUANTITATIVE CANCER RISK ASSESSMENT OF NONGENOTOXIC CARCINOGENS (Rafael Meza, Jihyoun Jeon, and Suresh H. Moolgavkar). References. CHAPTER 26 NONLINEAR LOW-DOSE EXTRAPOLATIONS (Ari S. Lewis and Barbara D. Beck). References. CHAPTER 27 CANCER RISK ASSESSMENT: MORE UNCERTAIN THAN WE THOUGHT (Edmund A. C. Crouch). References. CHAPTER 28 COMBINING NEOPLASMS FOR EVALUATION OF RODENT CARCINOGENESIS STUDIES (Amy E. Brix, Jerry F. Hardisty, and Ernest E. McConnell). References. CHAPTER 29 CANCER RISK BASED ON AN INDIVIDUAL TUMOR TYPE OR SUMMING OF TUMORS (Andrew G. Salmon and Lindsey A. Roth). References. CHAPTER 30 EXPOSURE RECONSTRUCTION AND CANCER RISK ESTIMATE DERIVATION (Shannon Gaffney, Jennifer Sahmel, Kathryn D. Devlin, and Dennis J. Paustenbach). References. INDEX.
PREFACE. CONTRIBUTORS. ABBREVIATIONS AND ACRONYMS. PART I CANCER RISK ASSESSMENT, SCIENCE POLICY, AND REGULATORY FRAMEWORKS. CHAPTER 1 CANCER RISK ASSESSMENT(Elizabeth L. Anderson, Kimberly Lowe, and Paul Turnham). References. CHAPTER 2 SCIENCE POLICY AND CANCER RISK ASSESSMENT (Gary E. Marchant). References. CHAPTER 3 HAZARD AND RISK ASSESSMENT OF CHEMICAL CARCINOGENICITY WITHIN A REGULATORY CONTEXT (Henk Tennekes, Virginia A. Gretton, and Todd Stedeford). References. CHAPTER 4 USE OF CANCER RISK ASSESSMENTS IN DETERMINATION OF REGULATORY STANDARDS (Robert A. Howd and Anna M. Fan). References. PART II CANCER BIOLOGY AND TOXICOLOGY. CHAPTER 5 THE INTERPLAY OF CANCER AND BIOLOGY (James W. Holder). References. CHAPTER 6 CHEMICAL CARCINOGENESIS: A BRIEF HISTORY OF ITS CONCEPTS WITH A FOCUS ON POLYCYCLIC AROMATIC HYDROCARBONS (Stephen Nesnow). References. CHAPTER 7 HORMESIS AND CANCER RISKS: ISSUES AND RESOLUTION (Paolo F. Ricci and Edward J. Calabrese). References. CHAPTER 8 THRESHOLDS FOR GENOTOXIC CARCINOGENS: EVIDENCE FROM MECHANISM-BASED CARCINOGENICITY STUDIES (Shoji Fukushima, Min Wei, Anna Kakehashi, and Hideki Wanibuchi). References. PART III GENETIC TOXICOLOGY, TESTING GUIDELINES AND REGULATIONS, AND NOVEL ASSAYS. CHAPTER 9 DEVELOPMENT OF GENETIC TOXICOLOGY TESTING AND ITS INCORPORATION INTO REGULATORY HEALTH EFFECTS TEST REQUIREMENTS (Errol Zeiger). References. CHAPTER 10 GENETIC TOXICOLOGY TESTING GUIDELINES AND REGULATIONS (Lutz Müller and Hans-Jörg Martus). References. CHAPTER 11 IN VITRO GENOTOX ASSAYS (David Kirkland and David Gatehouse). References. CHAPTER 12 IN VIVO GENOTOXICITY ASSAYS (Véronique Thybaud). References. PART IV ASSESSING THE HUMAN RELEVANCE OF CHEMICAL-INDUCED TUMORS. CHAPTER 13 FRAMEWORK ANALYSIS FOR DETERMINING MODE OF ACTION AND HUMAN RELEVANCE (R. Julian Preston). References. CHAPTER 14 EXPERIMENTAL ANIMAL STUDIES AND CARCINOGENICITY (Mary Elizabeth (Bette) Meek). References. CHAPTER 15 CANCER EPIDEMIOLOGY (Herman J. Gibb and Jessie P. Buckley). References. CHAPTER 16 RODENT HEPATOCARCINOGENESIS (James E. Klaunig). References. CHAPTER 17 MODE OF ACTION ANALYSIS AND HUMAN RELEVANCE OF LIVER TUMORS INDUCED BY PPARa ACTIVATION (J. Christopher Corton). References. CHAPTER 18 ALPHA2U-GLOBULIN NEPHROPATHY AND CHRONIC PROGRESSIVE NEPHROPATHY AS MODES OF ACTION FOR RENAL TUBULE TUMOR INDUCTION IN RATS, AND THEIR POSSIBLE INTERACTION (Edward A. Lock and Gordon C. Hard). References. CHAPTER 19 URINARY TRACT CALCULI AND BLADDER TUMORS (Samuel M. Cohen, Lora L. Arnold, and Shugo Suzuki). References. PART V METHODS FOR INFORMING CANCER RISK QUANTIFICATION. CHAPTER 20 (Q)SAR ANALYSIS OF GENOTOXIC AND NONGENOTOXIC CARCINOGENS: A STATE-OF-THE-ART OVERVIEW (Yin-tak Woo and David Y. Lai). References. CHAPTER 21 PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELS IN CANCER RISK ASSESSMENT (Mathieu Valcke and Kannan Krishnan). References. CHAPTER 22 GENOMICS AND ITS ROLE IN CANCER RISK ASSESSMENT (Banalata Sen, Douglas C. Wolf, and Vicki Dellarco). References. CHAPTER 23 COMPUTATIONAL TOXICOLOGY IN CANCER RISK ASSESSMENT (Jerry N. Blancato). References. PART VI GENERAL APPROACHES FOR QUANTIFYING CANCER RISKS. CHAPTER 24 LINEAR LOW-DOSE EXTRAPOLATIONS (Michael Dourson and Lynne Haber). References. CHAPTER 25 QUANTITATIVE CANCER RISK ASSESSMENT OF NONGENOTOXIC CARCINOGENS (Rafael Meza, Jihyoun Jeon, and Suresh H. Moolgavkar). References. CHAPTER 26 NONLINEAR LOW-DOSE EXTRAPOLATIONS (Ari S. Lewis and Barbara D. Beck). References. CHAPTER 27 CANCER RISK ASSESSMENT: MORE UNCERTAIN THAN WE THOUGHT (Edmund A. C. Crouch). References. CHAPTER 28 COMBINING NEOPLASMS FOR EVALUATION OF RODENT CARCINOGENESIS STUDIES (Amy E. Brix, Jerry F. Hardisty, and Ernest E. McConnell). References. CHAPTER 29 CANCER RISK BASED ON AN INDIVIDUAL TUMOR TYPE OR SUMMING OF TUMORS (Andrew G. Salmon and Lindsey A. Roth). References. CHAPTER 30 EXPOSURE RECONSTRUCTION AND CANCER RISK ESTIMATE DERIVATION (Shannon Gaffney, Jennifer Sahmel, Kathryn D. Devlin, and Dennis J. Paustenbach). References. INDEX.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
